Skip to main content
. Author manuscript; available in PMC: 2018 Apr 1.
Published in final edited form as: Arterioscler Thromb Vasc Biol. 2017 Feb 2;37(4):664–674. doi: 10.1161/ATVBAHA.116.308791

Figure 1. Patients taking tamoxifen have altered platelet function and diminished platelet angiogenic potential.

Figure 1

Platelets were isolated from patients on tamoxifen maintenance therapy or healthy controls and activated by exposure to MCF-7 breast tumor cells for 10 minutes to generate an “activated platelet releasate” (A). Activation was determined by P-selectin surface expression using flow cytometry following activation with MCF-7 tumor cells (B). VEGF release from platelets was measured in resulting releastes by ELISA (C). MCF-7 activated or resting platelet releasates from patients were used in capillary tubes assays and compared to releasates from healthy controls. Representative images are shown (D) and results from all replicates are quantified (E). Bars indicate SEM. P<*0.05 by ANOVA, n=3–6 independent replicates per treatment group. Scale bars represent 100 µm.